175
Views
2
CrossRef citations to date
0
Altmetric
Editorials

‘Prodromal diagnosis’ of psychosis: an impartial commentary

(Professorial Fellow and NHMRC Australia Fellow)
Pages 520-523 | Published online: 30 May 2011

References

  • Rosenman S, Anderson P. Does prodromal diagnosis delay early intervention? Aust NZ J Psychiatry 2011; 45:509–514.
  • McGorry PD. Pre-emptive intervention in psychosis: agnostic rather than diagnostic. Aust NZ J Psychiatry 2011; 45:515–519.
  • Correll CU, Hauser M, Auther AM, Cornblatt BA. Research in people with psychosis risk syndrome: a review of the current evidence and future directions. J Child Psychol Psychiatry 2010; 51:390-431.
  • Yung AR, Nelson B. Young people at ultra high risk for psychosis: a research update. Early Interv Psychiatry 2011; 5:S52–57.
  • McGorry P, Killackey E, Lambert T . Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust NZ J Psychiatry 2005; 39:1–30.
  • Woods SW, Walsh BC, Saksa JR, McGlashan TH. The case for including Attenuated Psychotic Symptoms Syndrome in DSM-5 as a psychosis risk syndrome. Schizophr Res 2010; 123:199–207.
  • McGorry PD, Hickie IB, Yung AR, Pantelis C, Jackson HJ. Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. Aust NZ J Psychiatry 2006; 40:616–622.
  • Frances A. Opening Pandora's box: the 19 worst suggestions for DSM5. Psychiatric Times 11 February 2010, www.psychiatrictimes.com/dsm/content/article/10168/1522341.
  • Preti A, Cella M. Randomized-controlled trials in people at ultra high risk of psychosis: a review of treatment effectiveness. Schizophr Res 2010; 123:30–36.
  • Moncrieff J. Questioning the ‘neuroprotective’ hypothesis: does drug treatment prevent brain damage in early psychosis or schizophrenia? Br J Psychiatry 2011; 198:85–87.
  • Amminger GP, Schafer MR, Papageorgiou K . Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2010; 67:146–154.
  • Rose G. Strategy of prevention: lessons from cardiovascular disease Br Med J (Clin Res Ed) 1981;282:1847–1851.
  • Cantor-Graae E. The contribution of social factors to the development of schizophrenia: a review of recent findings. Can J Psychiatry 2007; 52:277–286.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.